CRDF

Neutral

Cardiff Oncology (CRDF) Unveils Promising Preclinical Data at AACR Meeting

Cardiff Oncology (CRDF) is presenting new preclinical data at the American Association for Cancer Research Annual Meeting, highlighting the efficacy o...

GuruFocus 3 days ago 0

Neutral

Cardiff Oncology (NASDAQ: CRDF) CFO awarded 486,650 stock options

Cardiff Oncology's CFO, Joshua B. Muntner, was granted 486,650 stock options with an exercise price of $1.58 per share, expiring on April 6, 2036. The...

Stock Titan 4 days ago 0